The American College of Surgeons Oncology Group Z1071 trial in 2013 demonstrated the fesability of sentinel lymph node biopsy in clinically node-positive patients following neoadjuvant chemotherapy. The goal of this study was to determine the continued impact of this study on our practice pattern.
Materials and Methods
This is a retrospective review of institutional changes in the management of axillary nodal disease following the publication of Z1071. Patients with clinically node-positive disease that completed neoadjuvant chemotherapy between 2014 and 2020 were included. The Cocoran-Armitage trend test was used to analyze change in categorical variables over time, and the Spearman’s rank coefficient was used to analyze two-ranked variables.
Results
A cohort of 102 patients were included in the study and demonstrated that the number of sentinel lymph node biopsies to evaluate axillary disease increased over time. Additionally, the number of biopsies of suspicious nodes, and the use of marker clips on the biopsied nodes increased over time.
Conclusion
Our institution has continued to incorporate the result from Z1071 in our practice patterns.
MougalianSSSoulosPRKilleleaBK, et al.Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States. Cancer. 2015;121(15):2544-2552. doi:10.1002/cncr.29348
2.
BitencourtARossi SaccarelliCMorrisEA, et al.Regional lymph node involvement among patients with de novo metastatic breast cancer. JAMA Netw Open. 2020;3(10):e2018790. doi:10.1001/jamanetworkopen.2020.18790
3.
AsselainBBarlowWBartlettJFlynnJZhangZKhanA, Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: Meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018;19(1):27-39. doi: 10.1016/S1470-2045(17)30777-5
4.
HennessyBTHortobagyiGNRouzierR, et al.Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol. 2005;23(36):9304-9311. doi:10.1200/jco.2005.02.5023
5.
Husted MadsenAHaugaardKSoerensenJ, et al.Arm morbidity following sentinel lymph node biopsy or axillary lymph node dissection: A study from the danish breast cancer cooperative group. Breast. 2008;17(2):138-147. doi:10.1016/j.breast.2007.08.006
6.
HelmsGKühnTMoserLRemmelEKreienbergR. Shoulder-arm morbidity in patients with sentinel node biopsy and complete axillary dissection—Data from a prospective randomised trial. Eur J Surg Oncol. 2009;35(7):696-701. doi:10.1016/j.ejso.2008.06.013
7.
BougheyJCSumanVJMittendorfEA, et al.Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: The ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455-1461. doi:10.1001/jama.2013.278932
8.
KuehnTBauerfeindIFehmT, et al.Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): A prospective, multicentre cohort study. Lancet Oncol. 2013;14(7):609-618. doi:10.1016/s1470-2045(13)70166-9
9.
BoileauJFPoirierBBasikM, et al.Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: The SN FNAC study. J Clin Oncol. 2015;33(3):258-264. doi:10.1200/jco.2014.55.7827
10.
BougheyJCBallmanKVLe-PetrossHT, et al.Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0-T4, N1-N2) who receive neoadjuvant chemotherapy: Results from ACOSOG Z1071 (Alliance). Ann Surg. 2016;263(4):802-807. doi:10.1097/SLA.0000000000001375
11.
DonkerMStraverMEWesselingJ, et al.Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: The MARI procedure. Ann Surg. 2015;261(2):378-382. doi:10.1097/sla.0000000000000558
12.
RugoHSOlopadeOIDeMicheleA, et al.Adaptive randomization of veliparib-carboplatin treatment in breast cancer. N Engl J Med. 2016;375(1):23-34. doi:10.1056/NEJMoa1513749
13.
von MinckwitzGSchneeweissALoiblS, et al.Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): A randomised phase 2 trial. Lancet Oncol. 2014;15(7):747-756. doi:10.1016/s1470-2045(14)70160-3
14.
BarronAUHoskinTLDayCNHwangESKuererHMBougheyJC. Association of low nodal positivity rate among patients with ERBB2-positive or triple-negative breast cancer and breast pathologic complete response to neoadjuvant chemotherapy. JAMA Surg. 2018;153(12):1120-1126. doi:10.1001/jamasurg.2018.2696
15.
KaratasFErdemGUSahinS, et al.Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients. Breast. 2017;32:237-244. doi:10.1016/j.breast.2016.05.013
16.
Chavez-MacgregorMLittonJChenH, et al.Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: Evaluating the effect of race/ethnicity. Cancer. 2010;116(17):4168-4177. doi:10.1002/cncr.25296
17.
de AzambujaEHolmesAPPiccart-GebhartM, et al.Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): Survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol. 2014;15(10):1137-1146. doi:10.1016/s1470-2045(14)70320-1
18.
ChristianNZaborECCassidyMFlynnJMorrowMGemignaniML. Contralateral prophylactic mastectomy use after neoadjuvant chemotherapy. Ann Surg Oncol. 2020;27(3):743-749. doi:10.1245/s10434-019-08038-8
19.
GusicLHWalshKFlippo-MortonTSarantouTBoselliDWhiteRLJr. Rationale for mastectomy after neoadjuvant chemotherapy. Am Surg. 2018;84(1):126-132.
20.
RastogiPAndersonSJBearHD, et al.Preoperative chemotherapy: Updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol. 2008;26(5):778-785. doi:10.1200/jco.2007.15.0235.
